Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation
- PMID: 28477008
- PMCID: PMC5522083
- DOI: 10.18632/oncotarget.17205
Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation
Abstract
Glioblastoma multiforme (GBM) is the most common and deadly brain cancer, characterized by its aggressive proliferation to adjacent tissue and high recurrence rate. We studied the efficacy and related mechanisms of the combination of cyclopamine (Cyp, a Sonic-hedgehog pathway (Shh) inhibitor) and temozolomide (TMZ, the clinically most used chemotherapeutic agent) in anti-GBM treatment. The micellarized Cyp (MCyp) showed better performance than Cyp solution in inhibiting GBM cells proliferation (3.77-fold against U87 MG cells and 3.28-fold against DBTRG-05MG cells) and clonogenity (1.35-fold against U87 MG cells and 2.17-fold against DBTRG-05MG cells), and preferred behavior of inhibiting cell invasion, colony formation through attenuated Gli1 expression. In addition, combination of MCyp and TMZ exhibited synergistic cytotoxicity, correlating with their ability in inducing apoptosis and eliminating neurospheres formation, and the combination of TMZ was accompanied with the enhanced blockage of Shh pathway. The optimal ratio of MCyp combined to TMZ was 1:20. So we proposed to use TMZ to kill tumor parenchyma and MCyp as the cancer stem cells inhibitor to resist tumor recurrence. These findings demonstrated that combination of TMZ with micellarized Cyp is a promising strategy for exerting different functions of drugs for tumor treatment.
Keywords: cyclopamine; glioma; hedgehog pathway; synergistic effect; temozolomide.
Conflict of interest statement
All the authors declare no conflicts of interests.
Figures










Similar articles
-
In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.Int J Cancer. 2012 Jul 15;131(2):E33-44. doi: 10.1002/ijc.27349. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22072503
-
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.Oncotarget. 2016 Nov 15;7(46):74860-74871. doi: 10.18632/oncotarget.11382. Oncotarget. 2016. PMID: 27556862 Free PMC article.
-
Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.J Exp Clin Cancer Res. 2019 Jun 18;38(1):266. doi: 10.1186/s13046-019-1264-2. J Exp Clin Cancer Res. 2019. PMID: 31215502 Free PMC article.
-
Essential role of Gli proteins in glioblastoma multiforme.Curr Protein Pept Sci. 2013 Mar;14(2):133-40. doi: 10.2174/1389203711314020005. Curr Protein Pept Sci. 2013. PMID: 23544423 Review.
-
Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):296-302. doi: 10.2176/nmc.ra.2018-0040. Epub 2018 Jun 13. Neurol Med Chir (Tokyo). 2018. PMID: 29899179 Free PMC article. Review.
Cited by
-
Connexin 43 and Sonic Hedgehog Pathway Interplay in Glioblastoma Cell Proliferation and Migration.Biology (Basel). 2021 Aug 12;10(8):767. doi: 10.3390/biology10080767. Biology (Basel). 2021. PMID: 34439999 Free PMC article.
-
Inhibiting the Growth of 3D Brain Cancer Models with Bio-Coronated Liposomal Temozolomide.Pharmaceutics. 2021 Mar 12;13(3):378. doi: 10.3390/pharmaceutics13030378. Pharmaceutics. 2021. PMID: 33809262 Free PMC article.
-
Combined Effects of Doxorubicin and Temozolomide in Cultured Glioblastoma Cells.Curr Health Sci J. 2022 Jul-Sep;48(3):263-269. doi: 10.12865/CHSJ.48.03.03. Epub 2022 Sep 30. Curr Health Sci J. 2022. PMID: 36815076 Free PMC article.
-
Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations.Clin Exp Med. 2025 Apr 13;25(1):117. doi: 10.1007/s10238-025-01631-0. Clin Exp Med. 2025. PMID: 40223032 Free PMC article. Review.
-
Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations.Front Immunol. 2022 Nov 22;13:1038096. doi: 10.3389/fimmu.2022.1038096. eCollection 2022. Front Immunol. 2022. PMID: 36483545 Free PMC article. Review.
References
-
- Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004;36:1046–1069. - PubMed
-
- Bernstein JJ, Woodard CA. Glioblastoma cells do not intravasate into blood vessels. Neurosurgery. 1995;36:124–132. - PubMed
-
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical